Jasbir Seehra - 07 Jan 2026 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role: CHIEF EXECUTIVE OFFICER, Director
Signature: /s/ Keith Regnante, Attorney-in-Fact
Issuer symbol: KROS
Transactions as of: 07 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 09 Jan 2026, 16:15:05 UTC
Previous filing: 05 Sep 2025
Next filing: 20 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Seehra Jasbir	CHIEF EXECUTIVE OFFICER, Director	C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON	/s/ Keith Regnante, Attorney-in-Fact	09 Jan 2026	0001732369

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KROS	Employee Stock Option (right to buy)	Award	$0	+62,500		$0.000000	62,500	07 Jan 2026	Common Stock	62,500	$63.61	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On February 23, 2024, the Reporting Person filed a Form 4 with the SEC reporting the grant of an option to purchase 125,000 shares of common stock, the vesting of which was subject to the achievement of specified performance criteria. On January 7, 2026, the Compensation Committee of the Issuer's Board of Directors certified that (i) certain performance condition with respect to the option to purchase 62,500 shares had been met, resulting in the immediate vesting of 31,250 shares and the vesting of 31,250 shares on December 31, 2026, subject to the continuous service of the Reporting Person through such date, and (ii) certain performance condition with respect to the option to purchase 62,500 shares had not been met, resulting in the forfeiture of such option for no consideration.

Content

On February 23, 2024, the Reporting Person filed a Form 4 with the SEC reporting the grant of an option to purchase 125,000 shares of common stock, the vesting of which was subject to the achievement of specified performance criteria. On January 7, 2026, the Compensation Committee of the Issuer's Board of Directors certified that (i) certain performance condition with respect to the option to purchase 62,500 shares had been met, resulting in the immediate vesting of 31,250 shares and the vesting of 31,250 shares on December 31, 2026, subject to the continuous service of the Reporting Person through such date, and (ii) certain performance condition with respect to the option to purchase 62,500 shares had not been met, resulting in the forfeiture of such option for no consideration.